Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs

Table 1

Baseline characteristics.

Parameter	⁢All patients ()		⁢Belotecan group ()		⁢Topotecan group ()		value
	Number of patients	%	Number of patients	%	Number of patients	%
Sex							0.054
Male	80	85.1	47	79.7	33	94.3
Female	14	14.9	12	20.3	2	5.7
Age, years							0.164
Median	67.8		68.8		65.8
Range	42–88		42–88		48–81
ECOG							0.715
0	17	18.1	10	16.9	7	20
1	48	51.1	31	52.5	17	48.6
2	18	19.1	11	18.6	7	20
3	10	10.6	7	11.9	3	8.6
4	1	1.1	0	0	1	2.9
Stage at diagnosis							0.330
Limited	44	46.8	32	54.2	12	34.3
IIa	2	2.1	2	3.4	0	0
IIb	1	1.1	1	1.7	0	0
IIIa	15	16	11	18.6	4	11.4
IIIB	26	27.7	18	30.5	8	22.9
Extensive	50	53.2	27	45.8	23	65.7
Response to prior CTx							0.088
CR or PR	11	11.7	10	16.9	1	2.9
SD or PD	55	58.5	36	61	19	54.3
CTx line							0.011
1	13	13.8	10	16.9	3	8.6
2	57	60.6	40	67.8	17	48.6
3	24	25.5	9	15.3	15	42.9

ECOG: Eastern Cooperative Oncology Group score, CTx: chemotherapy, CR: complete response, PR: partial response, SD: stable disease, and PD: progressive disease.